Cannabis Mental Health Treatment Faces Doubts After Major Study

Published: 17 March 2026. The English Chronicle Desk. The English Chronicle Online.

A major new review has raised serious concerns about cannabis mental health treatment, challenging growing global demand. Researchers found little convincing evidence that cannabis-based therapies effectively treat common psychiatric conditions. The findings arrive as more patients worldwide turn to medicinal cannabis for anxiety and related disorders. Despite rising popularity, experts warn that expectations may be far ahead of scientific reality.

The comprehensive study, published in The Lancet Psychiatry, examined a wide range of clinical trials. Researchers analysed 54 randomised controlled trials involving 2,477 participants across multiple countries and conditions. The team included specialists from leading institutions in Australia and the United Kingdom. Their work represents the largest and most detailed assessment of cannabis mental health treatment evidence to date.

The results were striking in their consistency. Researchers concluded there was very little evidence supporting cannabis mental health treatment effectiveness. Conditions such as anxiety, anorexia nervosa, and psychotic disorders showed no meaningful improvement. The same was true for post-traumatic stress disorder and opioid use disorder outcomes. These findings directly challenge widespread claims that cannabis offers therapeutic psychiatric benefits.

The growing use of medicinal cannabis has been partly driven by legal changes across several countries. Nations including the United States, the United Kingdom, Australia, and Canada have expanded access. Clinics prescribing cannabis-based treatments have increased rapidly, especially in urban areas. Many patients seek these therapies believing they provide safer alternatives to traditional medications.

Data from medical cannabis clinics suggests mental health concerns are the primary reason for prescriptions. Anxiety and depression are frequently cited by patients seeking relief through cannabis-based products. Chronic pain often follows as another common reason for medical cannabis use. Some patients report experiencing both physical and psychological symptoms simultaneously, further complicating treatment decisions.

However, the review suggests that such expectations may not align with clinical evidence. Researchers found no significant improvements across several key mental health outcomes. The absence of strong data raises concerns about how cannabis mental health treatment is being promoted. Experts stress that patient demand should not outpace reliable scientific validation.

There were some limited findings suggesting potential benefits in other areas. Cannabis-based treatments may help reduce dependence in certain substance use disorders. Some evidence also indicated improvements in sleep among individuals experiencing insomnia. Additionally, researchers observed modest reductions in symptoms associated with Tourette syndrome.

The study also explored potential effects on autism spectrum disorder traits. While some positive outcomes were noted, the evidence quality was described as low. This means conclusions remain uncertain and require further investigation through more rigorous trials. Experts caution against drawing strong clinical recommendations from such limited findings.

Importantly, the review found no evidence supporting cannabis use for treating depression. This absence is particularly significant given how widely cannabis is used for mood-related symptoms. Researchers emphasised the need for high-quality trials to address this critical gap in evidence. Without such data, clinicians cannot confidently recommend cannabis mental health treatment for depressive conditions.

The findings have sparked strong reactions from leading psychiatric experts. Sir Robin Murray of King’s College London voiced serious concerns about current trends. He argued that the perceived benefits of cannabis are often overstated in public discussions. According to him, side effects are common and frequently underestimated by patients and providers alike.

He also criticised the rapid expansion of cannabis clinics in the United Kingdom. In his view, some clinics may prioritise commercial interests over patient wellbeing. He suggested that the industry’s influence has contributed to widespread misconceptions about cannabis mental health treatment. These comments reflect growing unease among traditional medical professionals.

On the other hand, representatives from the cannabis industry strongly dispute these conclusions. Mike Morgan-Giles of the Cannabis Industry Council defended current practices. He highlighted real-world evidence suggesting cannabis can reduce anxiety and PTSD symptoms. According to him, patient outcomes in clinical settings often differ from controlled trial findings.

Morgan-Giles also criticised the review for not fully reflecting how treatments are prescribed in practice. He argued that clinical decisions are tailored to individual patient needs and circumstances. This perspective underscores an ongoing divide between academic research and industry experience. Both sides agree, however, that more research is urgently needed.

The debate comes as UK regulators continue to evaluate cannabis policy and its wider impact. The Advisory Council on the Misuse of Drugs is currently reviewing the 2018 legalisation of cannabis-based products. The review aims to assess both intended outcomes and any unintended consequences. This includes examining whether increased access has led to misuse or unrealistic expectations.

Medical professionals stress the importance of clear and transparent communication with patients. Owen Bowden-Jones from the Royal College of Psychiatrists emphasised informed decision-making. He noted that patients must understand both the potential benefits and limitations of cannabis-based treatments. Without accurate information, individuals may make choices that do not support their long-term health.

He described the review as the clearest indication yet that cannabis benefits may be overstated. While acknowledging some modest advantages in specific cases, he warned against widespread use. He stressed that cannabis mental health treatment should not be offered where no proven benefit exists. This cautious approach reflects broader concerns within the psychiatric community.

The study’s findings highlight a critical gap between public perception and scientific evidence. Cannabis has gained a reputation as a natural and effective remedy for various conditions. However, the reality appears far more complex and uncertain. Experts warn that relying on unproven treatments may delay access to more effective therapies.

This issue is particularly important in the context of rising mental health challenges worldwide. Anxiety, depression, and related conditions continue to affect millions of people. Effective, evidence-based treatments are essential for improving outcomes and quality of life. Policymakers and healthcare providers must ensure that patients receive appropriate care grounded in science.

The growing popularity of cannabis also reflects broader shifts in attitudes towards alternative medicine. Many individuals are seeking treatments perceived as more natural or less invasive. While this trend has positive aspects, it also carries risks if not supported by strong evidence. The cannabis mental health treatment debate illustrates the need for balanced, informed discussions.

Researchers behind the study have called for further high-quality clinical trials. They emphasise the importance of robust methodologies and larger participant groups. Such research is essential to determine whether cannabis has any meaningful role in psychiatric care. Until then, caution remains the prevailing recommendation among experts.

As the conversation continues, patients, clinicians, and policymakers face difficult decisions. Balancing hope, evidence, and patient autonomy is never straightforward in healthcare. The findings from this review provide an important foundation for future discussions. Ultimately, ensuring patient safety and effective treatment must remain the highest priority.